Mortality predictors in a cohort of patients with COVID-19 admitted to a large tertiary hospital in the city of São Paulo, Brazil
Keywords:
SARS-CoV-2, COVID-19, Mortality, Hospitalization, PrognosisAbstract
BACKGROUND: There is discrepant information across countries regarding the natural history of patients admitted to hospitals with coronavirus disease (COVID-19), in addition to a lack of data on the scenario in Brazil. OBJECTIVE: To determine the mortality predictors in COVID-19 patients admitted to a tertiary hospital in São Paulo, Brazil. DESIGN AND SETTING: A retrospective analysis of medical records of COVID-19 patients admitted to the Hospital Central da Irmandade da Santa Casa de Misericórdia of São Paulo. METHODS: Overall, 316 patients with laboratory-confirmed COVID-19 between March 1, 2020, and July 31, 2020, were included. The analysis included the baseline characteristics, clinical progression, and outcomes. RESULTS: The mortality rate of the sample was 51.27%. Age ≥ 60 years was determined as a risk factor after multivariate logistic regression analysis. Patients with an oxygen (O2) saturation ≤ 94% upon admission accounted for 87% of the deaths (P < 0.001). Vasoactive drugs were used in 92% (P < 0.001) of patients who progressed to death, and mechanical ventilation was employed in 88% (P < 0.001) of such patients. However, patients who received corticosteroids concomitantly with mechanical ventilation had a better prognosis than those who did not. The progressive degree of pulmonary involvement observed on chest computed tomography was correlated with a worse prognosis. The presence of thrombocytopenia has been considered as a risk factor for mortality. CONCLUSION: The main predictors of in-hospital mortality after logistic regression analysis were age, O2 saturation ≤ 94% upon admission, use of vasoactive drugs, and presence of thrombocytopenia.
Downloads
References
World Health Organization. Pneumonia of unknown cause – China. COVID-19 - China. Available from: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. Accessed in 2022 (Jun 13).
World Health Organization. WHO Statement regarding cluster of pneumonia cases in Wuhan, China. Available from: https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china. Accessed in 2022 (Jun 13).
World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. Available from: https://www.who. int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed in 2022 (Jun 13).
Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020;52(11):549-57. PMID: 32991251; https://doi.org/10.1152/physiolgenomics.00089.2020.
Gautret P, Million M, Jarrot PA, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020;16(12):1159-84. PMID: 33356661; https://doi.org/10.1080/1744666X.2021.1847640.
World Health Organization. Coronavirus disease (COVID-19). Situation report - 193. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200731-covid-19-sitrep-193.pdf?sfvrsn=42a0221d_4. Accessed in 2022 (Jun 13).
Brasil. Ministério da Saúde. Diretrizes Estratégicas. Available from: https://bvsms.saude.gov.br/bvs/pacsaude/diretrizes.php. Accessed in 2022 (Jun 22).
World Health Organization. COVID-19 clinical management: living guidance, 25 January 2021. Available from: https://apps.who.int/iris/handle/10665/338882.Accessed in 2022 (Jun 13).
World Health Organization. Active ageing - A policy framework. Geneva: World Health Organization; 2002. Available from: https://apps.who.int/iris/bitstream/handle/10665/67215/WHO_NMH_NPH_02.8.pdf?sequence=1&isAllowed=y. Accessed in 2022 (Jun 13).
World Health Organization. ICD-10: International statistical classification of diseases and related health problems: tenth revision [Internet]. 2nd ed. Geneva: World Health Organization; 2004. Available from: https://apps.who.int/iris/bitstream/handle/10665/42980/9241546530_eng.pdf?sequence=1&isAllowed=y. Accessed in 2022 (Jun 13).
Pastore CA, Pinho JA, Pinho C, et al. III Diretrizes da Sociedade Brasileira De Cardiologia sobre análise e emissão de laudos eletrocardiográficos. Arq Bras Cardiol. 2016;106(4 Supl.1):1-23. PMID: 27096665; https://doi.org/10.5935/abc.20160054.
Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. Update in: BMJ. 2020;371:m4475. Update in: BMJ. 2021;372:n860. Update in: BMJ. 2021;374:n1703. Update in: BMJ. 2021;374:n2219. Erratum in: BMJ. 2022;377:o1045. PMID: 32887691; https://doi.org/10.1136/bmj.m3379.
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9. Erratum in: JAMA. 2020;323(20):2098. PMID: 32320003; https://doi.org/10.1001/jama.2020.6775.
Bellan M, Patti G, Hayden E, et al. Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. Sci Rep. 2020;10(1):20731. PMID: 33244144; https://doi.org/10.1038/s41598-020-77698-4.
Santos MM, Lucena EES, Lima KC, et al. Survival and predictors of deaths of patients hospitalised due to COVID-19 from a retrospective and multicentre cohort study in Brazil. Epidemiol Infect. 2020;148:e198. PMID: 32892789; https://doi.org/10.1017/S0950268820002034.
Kichloo A, Dettloff K, Aljadah M, et al. COVID-19 and hypercoagulability: a review. Clin Appl Thromb Hemost. 2020;26:1076029620962853. PMID: 33074732; https://doi.org/10.1177/1076029620962853.